Glucagon as a target for the treatment of Type 2 diabetes

Author： Sloop Kyle W Michael M Dodson Moyers Julie S

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.9, Iss.3, 2005-06, pp. : 593-600

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glucagon antagonists for the treatment of Type 2 diabetes

By Connell R.D.

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 6, 1999-06 ,pp. : 701-709

Informa Healthcare

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1

By Holst J.J.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1409-1415

Informa Healthcare

Access to resources Recommend Favorite

SHIP2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 3, Iss. 4, 2003-12 ,pp. : 291-298

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus

Current Clinical Pharmacology, Vol. 12, Iss. 4, 2018-04 ,pp. : 202-209

Bentham Science Publishers

Access to resources Recommend Favorite

Progress towards glucagon receptor antagonist therapy for Type 2 diabetes

By Kurukulasuriya Ravi Link JT

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 12, 2005-12 ,pp. : 1739-1749

Informa Healthcare

Access to resources Recommend Favorite